What Research Can You Find About The New Weight Loss
According to a study, tirzepatide drugs such as Mounjaro and Zepbound may result in a greater weight loss of 26% in one year. Novo Nordisk, the company behind Ozempic and Wegovy, claimed the study is not a fair comparison. However, their rival company found success in their newly approved drug Zepbound, which was discovered by accident to promote weight loss by exposing the brain to a natural hormone at levels never seen in nature. This drug may be even more effective than Wegovy and could bring down the cost of treatment. FDA-approved for weight loss, Wegovy and self-injection drug Ozempic have been used for diabetes treatment. Further research is needed to fully understand the effects and effectiveness of these drugs.
Research suggests that tirzepatide-based drugs, such as Mounjaro and Zepbound, have demonstrated significant promise in weight loss trials, with a reported greater weight loss of 26% in one year. Novo Nordisk, the pharmaceutical company responsible for Ozempic and Wegovy, has contended that the study does not present a fair comparison. However, their competitor has found success with their newly approved drug Zepbound. This drug was discovered by chance to promote weight loss by exposing the brain to a natural hormone at levels unprecedented in nature. It is speculated to potentially outperform Wegovy and might also reduce treatment costs. Both Wegovy and the self-injection drug Ozempic are FDA-approved for weight loss, despite originally being used for diabetes treatment. Future research is required to fully comprehend the effects and efficacy of these drugs.
Sources
Related Questions
Work fast from anywhere
Stay up to date and move work forward with BrutusAI on macOS/iOS/web & android. Download the app today.